Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.
AAPS PharmSciTech
; 22(5): 172, 2021 Jun 07.
Article
in En
| MEDLINE
| ID: mdl-34100150
Key words
BNT162b1; BNT162b2; BioNTech; COVID-19; Pfizer; SARS-CoV-2; adolescents; adverse effects; antibody response; children; clinical trials; efficacy; phase 1 trials; phase 1/2 trials; phase 2 trials; phase 2/ 3 trials; phase 3 trials; preclinical trials; pregnant women; real-world outcomes; safety; tozinameran; vaccine
Full text:
1
Database:
MEDLINE
Main subject:
Clinical Trials as Topic
/
Drug Approval
/
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
Type of study:
Clinical_trials
/
Prognostic_studies
Language:
En
Journal:
AAPS PharmSciTech
Year:
2021
Type:
Article
Affiliation country:
Saint Vincent and the Grenadines